CHICAGO, July 2, 2024 /PRNewswire/ - SGS North America
(SGS) announced today that it has added new capacity and
capabilities to bolster its biologics testing services for the
American biopharmaceuticals market. This expansion brings new
instrumentation and scientific expertise to the SGS Lincolnshire
Center of Excellence, which services pharmaceutical,
biopharmaceutical, and medical device manufacturers and producers
across the United States.
The SGS Center of Excellence in Lincolnshire, Illinois is a 60,000
square-foot, state-of-the-art facility, delivering microbiology,
chemistry, and biologics testing and analysis services to support
clients with both small and large molecule testing. The site offers
innovative biopharmaceutical testing and product quality control
solutions for every stage of the product development
lifecycle. These stages span early cell bank safety
assessment and product characterization, to method development and
raw material testing, all the way through to the final stage of
product release.
Through this expansion, SGS has enhanced its instrumentation,
its specialized biologics expertise, and its capacity to support
characterization of novel biologics and biosimilars. These
enhancements also facilitate analytical testing in both the
discovery and commercial stages within a single facility,
delivering a comprehensive, streamlined, and flexible service
delivery approach to clients. This is timely given the
fast-growing needs of biopharmaceutical companies seeking to
accelerate getting their drugs to market cost-effectively. This
race to market also necessitates the ability to demonstrate that
regulatory guidelines are being met, which goes hand in hand with
quality and safety assurance. These factors often lead companies to
outsource their complex and specialized testing and analysis
requirements.
"Biologics constitute a high-growth segment of the
pharmaceutical market, with sales and development of
biologics-based products more than doubling over the last decade in
North America," said Derick Govender, Head of SGS North America.
"With the addition of scientific expertise and leading
instrumentation at our Lincolnshire site, SGS is bolstering its
biologics testing capabilities to better meet the growing demand
for large molecule drug products that are supporting rapid
advancements in novel drug discovery."
SGS North America is a network
of contract service laboratories providing pharmaceutical
development, biologics testing and characterization, biosafety, and
quality control testing. Its second Center of Excellence, that also
delivers biologics testing in North
America, is based in Mississauga,
Canada. SGS operates 20 laboratories across 11 countries
that service the global pharmaceutical industry. In this respect,
SGS represents the broadest, wholly owned, global network of
contract analytical laboratories for this sector. SGS also delivers
solutions for medical-device manufacturers and offers biostatistics
and regulatory consultancy.
About SGS
As the world's leading inspection, verification, testing and
certification company, SGS is recognized as the global benchmark
for quality and integrity. With more than 99,600 employees, SGS
operates a network of over 2,600 offices and laboratories around
the world. Visit www.sgs.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sgs-north-america-announces-expansion-of-biologics-testing-capabilities-302188449.html
SOURCE SGS North America Inc.